HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies
Doug Coyle(University of Ottawa), Koonal Shah(Office Of Health Economics), Louise Longworth(Bielefeld University), Stephen Palmer(University of York), Louis P. Garrison(University of Washington), Zack Pemberton‐Whiteley(Advocates for Youth), Isabelle Durand‐Zaleski(Inserm), Anne-Sophie Moutié(Dorset HealthCare University NHS Foundation Trust), Jasmine Farrington, Aurélie Meunier, Doug Sproule, Jie Shen(Los Angeles County Department of Public Health), Kun Zhao(Vanderbilt University Medical Center), Wolfgang Greiner(Bielefeld University), Mark Ratcliffe, Johann‐Matthias Graf von der Schulenburg(Leibniz University Hannover)
Cited by 70
Related Papers
Barriers and Strategies in Guideline Implementation—A Scoping Review
|Healthcare|2016|946
Development of the EQ-5D-Y: a child-friendly version of the EQ-5D
|Quality of Life Research|2010|903
German Value Set for the EQ-5D-5L
|PharmacoEconomics|2018|618
Feasibility, reliability, and validity of the EQ-5D-Y: results from a multinational study
|Quality of Life Research|2010|476
A single European currency for EQ-5D health states
|The European Journal of Health Economics|2003|465